{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T20:34:18Z","timestamp":1794170058769,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"NIH NCI","award":["R21CA167038"],"award-info":[{"award-number":["R21CA167038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0318-6","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T13:05:29Z","timestamp":1474463129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Ruifen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenan","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Julie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"issue":"9951","key":"318_CR1","first-page":"1376","volume":"384","author":"C Gordon","year":"2014","unstructured":"Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Ovarian cancer. The Lancet 2014;384(9951):1376\u201388.","journal-title":"Ovarian cancer. The Lancet"},{"key":"318_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"318_CR3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.4263","volume":"231","author":"CP Crum","year":"2013","unstructured":"Crum CP, Herfs M, Ning G, et al. Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol. 2013;231:402\u201312.","journal-title":"J Pathol"},{"key":"318_CR4","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315\u20139.","journal-title":"Cancer Res"},{"key":"318_CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2008.200","volume":"85","author":"B Rubio-Viqueira","year":"2009","unstructured":"Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"318_CR6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21:1318\u201325.","journal-title":"Nat Med"},{"key":"318_CR7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","volume":"170","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170:793\u2013804.","journal-title":"Am J Pathol"},{"key":"318_CR8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov"},{"key":"318_CR9","doi-asserted-by":"crossref","unstructured":"Scott CL, Mackay HJ, Haluska P, Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014;e258-266.","DOI":"10.14694\/EdBook_AM.2014.34.e258"},{"key":"318_CR10","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/cncr.28900","volume":"120","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Ubago J, Li L, et al. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer. 2014;120:3165\u201377.","journal-title":"Cancer"},{"key":"318_CR11","doi-asserted-by":"crossref","first-page":"10816","DOI":"10.18632\/oncotarget.2522","volume":"5","author":"R Dong","year":"2014","unstructured":"Dong R, Liu X, Zhang Q, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014;5:10816\u201329.","journal-title":"Oncotarget"},{"key":"318_CR12","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-13-0982","volume":"13","author":"X Xu","year":"2014","unstructured":"Xu X, Ayub B, Liu Z, et al. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice. Mol Cancer Ther. 2014;13:1729\u201339.","journal-title":"Mol Cancer Ther"},{"key":"318_CR13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","volume":"20","author":"SJ Weroha","year":"2014","unstructured":"Weroha SJ, Becker MA, Enderica-Gonzalez S, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014;20:1288\u201397.","journal-title":"Clin Cancer Res"},{"key":"318_CR14","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","volume":"65","author":"SA Bapat","year":"2005","unstructured":"Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65:3025\u20139.","journal-title":"Cancer Res"},{"key":"318_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00016347709158340","volume":"56","author":"M Davy","year":"1977","unstructured":"Davy M, Mossige J, Johannessen JV. Heterologous growth of human ovarian cancer. A new in vivo testing system. Acta Obstet Gynecol Scand. 1977;56:55\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"318_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0090-8258(84)90075-1","volume":"17","author":"JA Stratton","year":"1984","unstructured":"Stratton JA, Micha JP, Rettenmaier MA, Braley PS, DiSaia PJ. Chemosensitivity testing of nonsolid tumors by the subrenal-capsule implant assay. Gynecol Oncol. 1984;17:185\u20138.","journal-title":"Gynecol Oncol"},{"key":"318_CR17","first-page":"2662","volume":"47","author":"BG Ward","year":"1987","unstructured":"Ward BG, Wallace K, Shepherd JH, Balkwill FR. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 1987;47:2662\u20137.","journal-title":"Cancer Res"},{"key":"318_CR18","first-page":"283","volume":"13","author":"X Fu","year":"1993","unstructured":"Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993;13:283\u20136.","journal-title":"Anticancer Res"},{"key":"318_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/gyno.1998.5238","volume":"72","author":"Y Xu","year":"1999","unstructured":"Xu Y, Silver DF, Yang NP, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol. 1999;72:161\u201370.","journal-title":"Gynecol Oncol"},{"key":"318_CR20","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.2373","volume":"5","author":"ZC Dobbin","year":"2014","unstructured":"Dobbin ZC, Katre AA, Steg AD, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014;5:8750\u201364.","journal-title":"Oncotarget"},{"key":"318_CR21","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014;111:17266\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"318_CR22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","volume":"8","author":"MD Topp","year":"2014","unstructured":"Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014;8:656\u201368.","journal-title":"Mol Oncol"},{"key":"318_CR23","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1073\/pnas.1005529108","volume":"108","author":"JM Stewart","year":"2011","unstructured":"Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011;108:6468\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"318_CR24","first-page":"845","volume":"9","author":"CF Verschraegen","year":"2003","unstructured":"Verschraegen CF, Hu W, Du Y, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003;9:845\u201352.","journal-title":"Clin Cancer Res"},{"key":"318_CR25","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","volume":"18","author":"A Vidal","year":"2012","unstructured":"Vidal A, Munoz C, Guillen MJ, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012;18:5399\u2013411.","journal-title":"Clin Cancer Res"},{"key":"318_CR26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fonc.2014.00171","volume":"4","author":"JW Groeneweg","year":"2014","unstructured":"Groeneweg JW, DiGloria CM, Yuan J, et al. Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. Front Oncol. 2014;4:171.","journal-title":"Front Oncol"},{"key":"318_CR27","doi-asserted-by":"crossref","first-page":"e28077","DOI":"10.1371\/journal.pone.0028077","volume":"6","author":"CK McCann","year":"2011","unstructured":"McCann CK, Growdon WB, Kulkarni-Datar K, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011;6:e28077.","journal-title":"PLoS One"},{"key":"318_CR28","first-page":"7556","volume":"61","author":"S Ghamande","year":"2001","unstructured":"Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001;61:7556\u201362.","journal-title":"Cancer Res"},{"key":"318_CR29","doi-asserted-by":"crossref","first-page":"e21121","DOI":"10.1371\/journal.pone.0021121","volume":"6","author":"MP Stany","year":"2011","unstructured":"Stany MP, Vathipadiekal V, Ozbun L, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6:e21121.","journal-title":"PLoS One"},{"issue":"1","key":"318_CR30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.29362","volume":"137","author":"J-W Lee","year":"2015","unstructured":"Jeong-Won Lee, Ji-Yoon Ryu, Gun Yoon, Hye-Kyung Jeon, Young-Jae Cho, Jung-Joo Choi, Sang Yong Song, In-Gu Do, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Byoung-Gie Kim, Duk-Soo Bae. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer. International Journal of Cancer 2015;137(1):221\u20139.","journal-title":"International Journal of Cancer"},{"key":"318_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2004.09.025","volume":"96","author":"CH Lee","year":"2005","unstructured":"Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol. 2005;96:48\u201355.","journal-title":"Gynecol Oncol"},{"key":"318_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.10.010","volume":"344","author":"P Malaney","year":"2014","unstructured":"Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344:1\u201312.","journal-title":"Cancer Lett"},{"key":"318_CR33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0090-8258(86)90066-1","volume":"25","author":"W Kleine","year":"1986","unstructured":"Kleine W. Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. Gynecol Oncol. 1986;25:65\u201372.","journal-title":"Gynecol Oncol"},{"key":"318_CR34","doi-asserted-by":"crossref","first-page":"e24420","DOI":"10.1371\/journal.pone.0024420","volume":"6","author":"RB Bankert","year":"2011","unstructured":"Bankert RB, Balu-Iyer SV, Odunsi K, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011;6:e24420.","journal-title":"PLoS One"},{"key":"318_CR35","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1158\/0008-5472.CAN-14-0274","volume":"74","author":"F Ricci","year":"2014","unstructured":"Ricci F, Bizzaro F, Cesca M, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014;74:6980\u201390.","journal-title":"Cancer Res"},{"key":"318_CR36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2008.03.011","volume":"110","author":"JZ Press","year":"2008","unstructured":"Press JZ, Kenyon JA, Xue H, et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD\/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 2008;110:256\u201364.","journal-title":"Gynecol Oncol"},{"key":"318_CR37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/gyno.2002.6819","volume":"87","author":"JC Elkas","year":"2002","unstructured":"Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol. 2002;87:200\u20136.","journal-title":"Gynecol Oncol"},{"key":"318_CR38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ijc.2910440320","volume":"44","author":"G Massazza","year":"1989","unstructured":"Massazza G, Tomasoni A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer. 1989;44:494\u2013500.","journal-title":"Int J Cancer"},{"key":"318_CR39","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/stem.236","volume":"27","author":"MD Curley","year":"2009","unstructured":"Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27:2875\u201383.","journal-title":"Stem Cells"},{"key":"318_CR40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5689","volume":"76","author":"GM Kolfschoten","year":"2000","unstructured":"Kolfschoten GM, Pinedo HM, Scheffer PG, Schluper HM, Erkelens CA, Boven E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol. 2000;76:362\u20138.","journal-title":"Gynecol Oncol"},{"key":"318_CR41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1078-0432.CCR-10-1382","volume":"17","author":"U Kortmann","year":"2011","unstructured":"Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011;17:783\u201391.","journal-title":"Clin Cancer Res"},{"key":"318_CR42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fonc.2013.00295","volume":"3","author":"CL Scott","year":"2013","unstructured":"Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295.","journal-title":"Front Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T22:51:26Z","timestamp":1657320686000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0318-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0318-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,21]]},"article-number":"92"}}